Pruritus and Pemphigoid in Nursing Home Patients

Overview

The primary objective of this observational study is to describe the prevalence of pruritus and pemphigoid in nursing home patients. Secondary outcomes are the relationships of demographic factors and medical risk factors with pemphigoid, including dementia and neuropsychiatric symptoms, medication use and Karnofsky score.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: January 1, 2018

Detailed Description

Pruritus or itch is the most common skin symptom in elderly patients and is estimated to affect more than 30% of nursing home patients. Clinical and experimental evidence suggests pruritus in elderly patients may be linked to pemphigoid. Pemphigoid is the most common autoimmune skin blistering diseases and mainly affects the elderly. It is successfully treatable with systemic therapy. However, pemphigoid is often missed as a cause of pruritus in elderly patients (nonbullous cutaneous pemphigoid). Although nursing home patients and patients with dementia in particular have the highest risk for development of pemphigoid, no study has been performed in this population so far. Including serological screening for pemphigoid in the diagnostic evaluation of chronic pruritus in nursing home patients may lead to the diagnosis of pemphigoid. Furthermore, chronic itch may be an unrecognized cause of neuropsychiatric symptoms in nursing home patients with dementia.

Interventions

  • Other: Blood sample
    • One extra blood sample of 10 ml will be taken during a routine venapunction for immunoserology testing.

Arms, Groups and Cohorts

  • Nursing home patients
    • Nursing home patients aged 65 years or above. One extra blood sample of 10 ml will be taken during a routine venapunction for immunoserology testing.

Clinical Trial Outcome Measures

Primary Measures

  • Presence of pruritus
    • Time Frame: Day 1
    • Presence and intensity of pruritus will be determined (hetero-)anamnestically with the Bullous Pemphigoid Disease Area Index (BPDAI) VAS score and derivative score for all subjects.
  • Detection of circulating pemphigoid specific IgG autoantibodies by indirect immunofluorescence on 1M salt-split human skin substrate
    • Time Frame: Day 1
    • IgG autoantibodies with epidermal side staining of artificial split; positive/negative, staining intensity IgG 1+,2+,3+
  • Detection of circulating pemphigoid specific IgG autoantibodies by indirect immunofluorescence microscopy on monkey esophagus substrate
    • Time Frame: Day 1
    • Anti-basement membrane zone IgG autoantibodies; positive/negative, staining intensity IgG 1+,2+,3+
  • Concentration of anti-BP180 NC16A IgG autoantibodies by ELISA
    • Time Frame: Day 1
    • Anti-BP180 NC16A IgG index; U/mL, cut-off value 9 U/mL
  • Concentration of anti-BP230 IgG autoantibodies by ELISA
    • Time Frame: Day 1
    • Anti-BP230 IgG index; U/mL, cut-off value 9 U/mL
  • Detection of circulating pemphigoid specific IgG autoantibodies by immunoblot of keratinocyte extract
    • Time Frame: Day 1
    • Presence/absence of circulating IgG autoantibodies against BP180 (180kDa) or BP230 (230kDa)

Secondary Measures

  • Age
    • Time Frame: Day 1
    • For all subjects
  • Sex
    • Time Frame: Day 1
    • For all subjects
  • Comorbidities
    • Time Frame: Day 1
    • Presence/absence of comorbidities dementia, cerebrovascular accident, Parkinson’s disease, other neurological disease or other diseases
  • Karnofsky Performance Scale
    • Time Frame: Day 1
    • 0% – 100%
  • Medication
    • Time Frame: Day 1
    • Registration of medication use for all subjects
  • Neuropsychiatric symptoms
    • Time Frame: Day 1
    • Neuropsychiatric Inventory – Nursing Home version in Dutch

Participating in This Clinical Trial

Inclusion Criteria

  • Inpatient of a nursing home – Age 65 years or above – Subject or their official representatives have signed informed consent Exclusion Criteria:

  • Age below 65 years – Subjects who do not have signed informed consent – Receiving treatment with any systemic immunosuppressive agents – Terminally ill patients with a life expectancy of less than 4 weeks

Gender Eligibility: All

Minimum Age: 65 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • M.F. Jonkman
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: M.F. Jonkman, MD PhD – University Medical Center Groningen
  • Overall Official(s)
    • Marcel Jonkman, MD PhD, Principal Investigator, University Medical Center Groningen

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.